S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
Log in
NASDAQ:PETQ

PetIQ Stock Forecast, Price & News

$37.43
-0.39 (-1.03 %)
(As of 01/15/2021 08:00 PM ET)
Add
Compare
Today's Range
$36.81
Now: $37.43
$38.39
50-Day Range
$28.78
MA: $33.65
$38.45
52-Week Range
$15.83
Now: $37.43
$38.99
Volume16,558 shs
Average Volume274,665 shs
Market Capitalization$1.07 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.5
PetIQ, Inc. operates as a pet medication and wellness company. It operates through two segments, Products and Services. The company offers prescription pet medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; and over-the-counter medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars. It also provides health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products The company offers its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a suite of services at community clinics and wellness centers hosted at pet retailers across 41 states, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. As of March 10, 2020, it operated through approximately 60,000 points of distribution across retail and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.
PetIQ logo

MarketRank

Overall MarketRank

1.58 out of 5 stars

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Drugs, proprietaries, & sundries
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PETQ
CUSIPN/A
Phone208-939-8900
Employees1,866

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$709.43 million
Cash Flow$1.44 per share
Book Value$11.60 per share

Profitability

Net Income$-11,450,000.00

Miscellaneous

Market Cap$1.07 billion
Next Earnings Date3/9/2021 (Estimated)
OptionableOptionable
$37.43
-0.39 (-1.03 %)
(As of 01/15/2021 08:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PETQ News and Ratings via Email

Sign-up to receive the latest news and ratings for PETQ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











PetIQ (NASDAQ:PETQ) Frequently Asked Questions

How has PetIQ's stock been impacted by Coronavirus (COVID-19)?

PetIQ's stock was trading at $22.59 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PETQ stock has increased by 65.7% and is now trading at $37.43.
View which stocks have been most impacted by COVID-19
.

Is PetIQ a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PetIQ in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PetIQ stock.
View analyst ratings for PetIQ
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than PetIQ?

Wall Street analysts have given PetIQ a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but PetIQ wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is PetIQ's next earnings date?

PetIQ is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for PetIQ
.

How were PetIQ's earnings last quarter?

PetIQ, Inc. (NASDAQ:PETQ) released its quarterly earnings data on Thursday, November, 5th. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.09 by $0.28. The company had revenue of $162.08 million for the quarter, compared to analyst estimates of $166.90 million. PetIQ had a positive return on equity of 4.47% and a negative net margin of 10.13%.
View PetIQ's earnings history
.

What price target have analysts set for PETQ?

4 brokers have issued twelve-month target prices for PetIQ's stock. Their forecasts range from $35.00 to $175.00. On average, they expect PetIQ's stock price to reach $76.25 in the next year. This suggests a possible upside of 103.7% from the stock's current price.
View analysts' price targets for PetIQ
or view Wall Street analyst' top-rated stocks.

Who are some of PetIQ's key competitors?

What other stocks do shareholders of PetIQ own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PetIQ investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Exelixis (EXEL), Intel (INTC), CVS Health (CVS), QUALCOMM (QCOM), Editas Medicine (EDIT) and Gilead Sciences (GILD).

Who are PetIQ's key executives?

PetIQ's management team includes the following people:
  • Mr. McCord Christensen, Chairman & CEO (Age 49)
  • Mr. John Newland, Chief Financial Officer (Age 57)
  • Mr. Michael A. Smith, Exec. VP of Products Division (Age 44, Pay $970.96k)
  • Ms. Susan Sholtis, Pres (Age 55)
  • Mr. Robert Michael Herrman, Gen. Counsel & Sec. (Age 52)
  • Dr. Lauren Olavessen D.V.M., Sr. VP & Chief Medical Officer

When did PetIQ IPO?

(PETQ) raised $86 million in an initial public offering (IPO) on Friday, July 21st 2017. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. Jefferies and William Blair acted as the underwriters for the IPO and Oppenheimer, Raymond James and SunTrust Robinson Humphrey were co-managers.

What is PetIQ's stock symbol?

PetIQ trades on the NASDAQ under the ticker symbol "PETQ."

Who are PetIQ's major shareholders?

PetIQ's stock is owned by a variety of retail and institutional investors. Top institutional investors include Xcel Wealth Management LLC (0.04%). Company insiders that own PetIQ stock include James Nathan Clarke, John Newland, Robert Michael Herrman, Susan Sholtis and Will Santana.
View institutional ownership trends for PetIQ
.

Which institutional investors are buying PetIQ stock?

PETQ stock was bought by a variety of institutional investors in the last quarter, including Xcel Wealth Management LLC. Company insiders that have bought PetIQ stock in the last two years include James Nathan Clarke, John Newland, and Robert Michael Herrman.
View insider buying and selling activity for PetIQ
or or view top insider-buying stocks.

How do I buy shares of PetIQ?

Shares of PETQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PetIQ's stock price today?

One share of PETQ stock can currently be purchased for approximately $37.43.

How big of a company is PetIQ?

PetIQ has a market capitalization of $1.07 billion and generates $709.43 million in revenue each year. The company earns $-11,450,000.00 in net income (profit) each year or $1.07 on an earnings per share basis. PetIQ employs 1,866 workers across the globe.

What is PetIQ's official website?

The official website for PetIQ is www.petiq.com.

How can I contact PetIQ?

PetIQ's mailing address is 923 S. Bridgeway Pl., EAGLE ID, 83616. The company can be reached via phone at 208-939-8900 or via email at [email protected]

This page was last updated on 1/19/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.